Allakos Inc (OQ:ALLK)

Mar 14, 2024 04:02 pm ET
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth...
Feb 26, 2024 07:02 am ET
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a...
Feb 12, 2024 11:45 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Feb 12, 2024 07:02 am ET
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the...
Feb 11, 2024 03:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Feb 07, 2024 05:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  
Feb 07, 2024 03:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Feb 06, 2024 04:00 am ET
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Feb 03, 2024 04:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation...
Feb 03, 2024 08:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Feb 02, 2024 08:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Feb 01, 2024 07:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Jan 31, 2024 08:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Jan 30, 2024 05:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Jan 30, 2024 08:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Jan 29, 2024 03:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Jan 27, 2024 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ: ALLK) for violations of the securities laws.
Jan 26, 2024 10:42 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation...
Jan 22, 2024 06:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
NEW YORK, Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Jan 18, 2024 03:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Jan 16, 2024 07:02 am ET
Allakos Announces a Restructuring to Focus on Development of AK006
Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 clinical...
Jan 16, 2024 07:00 am ET
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic...
Nov 13, 2023 04:02 pm ET
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter...
Aug 30, 2023 04:05 pm ET
Allakos Appoints Neil Graham to its Board of Directors
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the...
Aug 09, 2023 04:02 pm ET
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second...
Aug 02, 2023 04:05 pm ET
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the...
Jun 12, 2023 07:02 am ET
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an...
Jun 05, 2023 07:02 am ET
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an...
May 09, 2023 04:02 pm ET
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter...
Mar 06, 2023 04:02 pm ET
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth...
Nov 29, 2022 07:02 am ET
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the...
Nov 10, 2022 09:02 am ET
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a...
Nov 07, 2022 04:05 pm ET
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third...
Oct 25, 2022 06:45 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 25, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.
Sep 19, 2022 08:33 am ET
Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro?
NEW YORK, Sept. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRPL, KNBE, ALLK, LRMR, and ALZN.
Sep 19, 2022 07:00 am ET
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock...
Sep 12, 2022 07:02 am ET
Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b clinical trial to evaluate the efficacy, safety and...
Sep 09, 2022 07:00 am ET
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today reported data from EoDyssey, a 24-week, Phase 3, randomized, double-blind,...
Aug 04, 2022 04:04 pm ET
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second...
Jul 25, 2022 04:05 pm ET
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and...
Jul 14, 2022 09:31 am ET
Thinking about buying stock in Clene, Canoo, EVgo, Payoneer Global, or Allakos?
NEW YORK, July 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLNN, GOEV, EVGO, PAYO, and ALLK.
Jun 10, 2022 11:10 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK
The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK) resulting from allegations that management may have issued materially misleading business information to the investing public.
Jun 09, 2022 05:20 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK
The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK) resulting from allegations that management may have issued materially misleading business information to the investing public.
May 06, 2022 04:05 pm ET
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first...
Mar 01, 2022 04:05 pm ET
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth...
Feb 01, 2022 08:00 am ET
Allakos to Host Investor Day on February 15
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it will host an Investor Day on February 15th...
Dec 23, 2021 09:45 am ET
Thinking about buying stock in Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, or Opko Health?
NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLK, XXII, OSMT, SAN, and OPK.
Dec 22, 2021 09:45 am ET
Thinking about buying stock in SeaChange International, Allakos, Petros Pharmaceuticals, Oscar Health, or Jaguar Health?
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, ALLK, PTPI, OSCR, and JAGX.
Dec 21, 2021 07:14 pm ET
Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIGMA 2, a 24-week Phase 3 randomized,...
Nov 30, 2021 07:00 am ET
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced it has initiated a randomized, double-blind,...
Nov 08, 2021 04:05 pm ET
Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third...
Oct 25, 2021 08:00 am ET
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing investigational medicine lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that its poster, “High Discovery Rate of...
Oct 24, 2021 03:35 pm ET
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American...
Aug 09, 2021 04:01 pm ET
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the second...
Jun 07, 2021 08:00 am ET
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it has completed enrollment in its Phase 3 study...
May 24, 2021 07:00 am ET
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointest
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, reported data at Digestive Disease Week (DDW) 2021. Results from a prospective...
May 10, 2021 04:01 pm ET
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and...
Apr 19, 2021 04:01 pm ET
Allakos Appoints Baird Radford as Chief Financial Officer
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial...
Mar 30, 2021 08:00 am ET
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster...
Mar 01, 2021 08:00 am ET
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year...
Dec 22, 2020 04:05 pm ET
Allakos Appoints Natalie Holles to its Board of Directors
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of...
Nov 09, 2020 08:01 am ET
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and...
Nov 02, 2020 08:00 am ET
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual...
Oct 28, 2020 08:19 pm ET
Allakos Announces Pricing of Public Offering of Common Stock
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering. The size of...
Oct 27, 2020 07:56 pm ET
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020. The...
Oct 27, 2020 04:08 pm ET
Allakos Announces Proposed Public Offering of Common Stock
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $250 million...
Oct 26, 2020 07:00 am ET
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced results from a Phase 1 Study of subcutaneously administered...
Oct 26, 2020 07:00 am ET
Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported results from a prospective study examining the rates of elevated...
Oct 21, 2020 05:00 pm ET
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Me
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind,...
Aug 10, 2020 08:00 am ET
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an update...
Jun 03, 2020 08:01 am ET
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that it is recruiting patients for two previously announced registrational clinical...
May 21, 2020 08:01 am ET
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of two oral abstract presentations at the upcoming...
May 11, 2020 10:03 am ET
ALLAKOS FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Allakos Inc. Investors of Deadline Today In Securities Class Action First Filed by Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Allakos investors under the federal securities laws.
May 11, 2020 08:01 am ET
Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting   
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at the upcoming American...
May 11, 2020 08:00 am ET
Allakos Reports First Quarter 2020 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020. First...
May 09, 2020 02:43 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 2-DAY APPLICATION DEADLINE ALERT, Investors with Losses Should Contact Firm Immediately
Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases, including the upcoming May 11, 2020 lead plaintiff...
May 09, 2020 12:22 pm ET
ALLAKOS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Allakos Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (“Allakos” or the “Company”) (NASDAQ:ALLK) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has...
May 08, 2020 04:00 pm ET
Safirstein Metcalf LLP Announces That A Class Action Has Been Filed Against Allakos, Inc.  - ALLK
Safirstein Metcalf LLP announces that a class action has been filed on behalf of investors that purchased the securities of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) between August 5, 2019 and December 17, 2019 (the “Class Period”)....
May 08, 2020 01:23 pm ET
ALLK INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors that only 3 Days Remain to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Allakos Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities...
May 08, 2020 12:00 pm ET
ALLAKOS FINAL DEADLINE, ROSEN, A TOP RANKED FIRM, Encourages Allakos Inc. Investors to Contact Firm Prior to May 11 Deadline For Class Action First Filed by Firm Seeking Recovery of Investor losses –
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff...
May 07, 2020 01:00 pm ET
ALLK DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Allakos Inc. Investors of Class Action and Lead Plaintiff Deadline: May 11, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or the Company”) (NASDAQ: ALLK) and certain of its officers, on behalf of shareholders who...
May 07, 2020 10:18 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of  Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
May 06, 2020 10:12 am ET
ALLK INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors That Only 5 Days Remain to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Allakos Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) between August 5, 2019 and December 17, 2019 (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities and Exchange Act of 1934.
May 04, 2020 03:45 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 7-DAY APPLICATION DEADLINE ALERT, Investors with Losses Should Contact Firm
Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases, including the upcoming May 11, 2020 lead plaintiff...
May 04, 2020 08:01 am ET
Allakos Announces Positive Interim Results from an Open-Label Extension Study of Antolimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported results from a long-term open-label extension (OLE) study of antolimab...
May 01, 2020 01:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Apr 30, 2020 06:23 pm ET
ALLK LOSS NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Allakos Inc. Investors of the Important May 11 Deadline in First Filed Securities Class Action Commenced By the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff...
Apr 29, 2020 11:00 am ET
ALLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Allakos Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Attorney Advertising-- NEW YORK--(PR Newswire)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or the Company”) (NASDAQ: ALLK) and certain of its officers, on behalf...
Apr 28, 2020 04:34 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALLK, CRON, FNKO Investors: 13-DAY DEADLINE ALERT, Investors with Losses Should Contact Firm
Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including the upcoming May 11, 2020 lead plaintiff application...
Apr 26, 2020 01:34 am ET
ALLAKOS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Allakos Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (“Allakos” or the “Company”) (NASDAQ:ALLK) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has...
Apr 23, 2020 03:30 pm ET
ROSEN, A TOP RANKED FIRM, Reminds Allakos Inc. Investors of the Important May 11th Deadline in First Filed Securities Class Action by the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff...
Apr 22, 2020 07:28 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALGN, ALLK, CRON, VMW Investors, Encourages Investors with Losses to Contact Firm, Reminds of Critical Upcoming Deadlines
Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases, including upcoming application deadlines, can be found at the...
Apr 21, 2020 08:01 am ET
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the...
Apr 15, 2020 07:30 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys Now: Securities Fraud Investor Deadlines Pending
Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims.  Class...
Apr 15, 2020 02:30 pm ET
ROSEN, A RANKED AND LEADING FIRM, Reminds Allakos Inc. Investors of the Important May 11th Deadline in First Filed Securities Class Action by the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff...
Apr 13, 2020 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Allakos Inc. Securities Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that the lead plaintiff motion deadline in the Allakos securities class action lawsuit is May 11, 2020. A securities class action lawsuit was filed in the Northern District of California on behalf of purchasers of Allakos Inc. (NASDAQ: ALLK) securities between August 5, 2019 an
Apr 11, 2020 09:00 am ET
ALLK LOSS NOTICE, ROSEN, A TOP FIRM, Reminds Allakos Inc. Investors With Large Losses of the May 11 Deadline in the Class Action Seeking Recovery of Investor Losses – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Allakos investors under the federal securities laws.
Apr 09, 2020 11:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Apr 09, 2020 05:52 pm ET
Shareholder Alert: Robbins LLP Announces It Is Investigating Allakos, Inc. (ALLK) for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that it is investigating Allakos, Inc. (NYSE: ALLK) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Allakos is a clinical stage biopharmaceutical company that focuses on d
Apr 09, 2020 09:15 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ALGN, ALLK, CCI Investors, Encourages Investors with Losses to Contact Firm: Important Deadlines Approaching
Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases can be found at the links provided. ALGN Investors Click...
Apr 07, 2020 10:00 am ET
WWE & ALLK INVESTOR UPDATE: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 01, 2020 08:27 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates AAN, ALGN, ALLK, CCI Investors, Encourages Investors with Losses to Contact Firm
Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases can be found at the links provided. AAN Investors Click...
Apr 01, 2020 07:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Apr 01, 2020 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Funko, Allakos, Cronos Group, and Gulfport Energy and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Funko, Inc. (NASDAQ: FNKO), Allakos, Inc. (NASDAQ: ALLK), Cronos Group, Inc....
Mar 30, 2020 03:51 pm ET
ALLAKOS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Allakos Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (“Allakos” or the “Company”) (NASDAQ:ALLK) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 29, 2020 10:00 am ET
ALLK LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Allakos Inc. Investors of Important Deadline in Securities Class Action First Filed by the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff...
Mar 28, 2020 11:41 am ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, March 28, 2020 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as
Mar 26, 2020 07:51 pm ET
Shareholder Alert: Robbins LLP Reminds Investors Allakos, Inc. (ALLK) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Allakos, Inc. (NASDAQ: ALLK) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 5, 2019 and December 17, 2019. Allakos is a clinical stage biopharmaceutical company that focuses o
Mar 26, 2020 09:42 am ET
ALLK CLASS ACTION DEADLINE: Bernstein Liebhard Announces that a Securities Class Action Lawsuit has been Filed Against Allakos Inc.
NEW YORK, March 26, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of Allakos Inc. ("Allakos" or the "Company") (NASDAQ: ALLK) between August 5, 2019 and December 17, 2019 (the "Class Period").  The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities and Exchange Act of 1934.
Mar 25, 2020 08:07 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Losses to Contact Its Attorneys: Application Deadline Approaching
Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims.  Class...
Mar 25, 2020 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against World Wrestling Entertainment, NMC Health, Funko, and Allakos and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of World Wrestling Entertainment, Inc. (NYSE: WWE), NMC Health PLC (Other OTC:...
Mar 25, 2020 03:28 pm ET
ALLK INVESTOR FILING DEADLINE: Bernstein Liebhard Announces that a Securities Class Action Lawsuit has been Filed Against Allakos Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) between August 5, 2019 and December 17, 2019 (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities and Exchange Act of 1934.
Mar 24, 2020 09:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. – ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Mar 24, 2020 04:01 pm ET
Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported results from a Phase 1 study evaluating the safety and efficacy of antolimab for the...
Mar 24, 2020 04:01 pm ET
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported the initiation of three clinical studies of antolimab: a Phase 3 study in eosinophilic...
Mar 20, 2020 03:00 pm ET
ALLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Allakos Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or the Company”) (NASDAQ: ALLK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Allakos securities between August 5, 2019 through December 17, 2019, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 19, 2020 12:00 pm ET
ALLK SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Alerts Allakos Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or “the Company”) (NASDAQ: ALLK) and certain of its officers, on behalf of shareholders who...
Mar 18, 2020 08:05 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Losses to Contact Its Attorneys: Application Deadline Approaching
Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now.  A securities fraud class action has been filed against the Company and certain investors may have valuable claims.  Class...
Mar 18, 2020 07:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Funko, Allakos, and Cronos Group and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Funko, Inc. (NASDAQ: FNKO), Allakos, Inc. (NASDAQ: ALLK), and Cronos Group, Inc....
Mar 17, 2020 07:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. – ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Mar 17, 2020 10:00 am ET
ALLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Allakos Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
NEW YORK, March 17, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. ("Allakos" or the Company") (NASDAQ: ALLK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Allakos securities between August 5, 2019 through December 17, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/allk.        
Mar 16, 2020 06:15 pm ET
ALLK LOSS NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Reminds Allakos Inc. Investors of Important Deadline in Securities Class Action First Filed by the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff...
Mar 16, 2020 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Allakos Inc. Securities Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Northern District of California on behalf of purchasers of Allakos Inc. (NASDAQ:ALLK) securities between August 5, 2019 and December 17, 2019 (the “Class Period”). The case is captioned Kim v. Allakos Inc., No. 20-cv-
Mar 13, 2020 04:15 pm ET
ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Allakos Inc. Investors of Important Deadline in Securities Class Action First Filed by the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Allakos investors under the federal securities laws.
Mar 13, 2020 03:00 pm ET
ALLK SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Alerts Allakos Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or “the Company”) (NASDAQ: ALLK) and certain of its officers, on behalf of shareholders who...
Mar 12, 2020 07:54 pm ET
Shareholder Alert: Robbins LLP Announces Allakos, Inc. (ALLK) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Allakos, Inc. (NYSE: ALLK) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 5, 2019 and December 17, 2019. Allakos is a clinical stage biopharmaceutical company that focuses on developing the
Mar 12, 2020 06:23 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed
Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now.  A securities fraud class action has been filed against the Company and certain investors may have valuable claims.  Class...
Mar 12, 2020 03:00 pm ET
ALLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Allakos Inc. Investors of Class Action and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or the Company”) (NASDAQ: ALLK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Allakos securities between August 5, 2019 through December 17, 2019, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Mar 12, 2020 09:23 am ET
ALLK LOSSES ALERT: Bernstein Liebhard Reminds Investors of its Investigation of the Allakos Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Allakos Inc. ("Allakos" or the "Company") (NASDAQ: ALLK) from allegations that Allakos might have...
Mar 12, 2020 08:51 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allakos Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Allakos Inc. (“Allakos” or “the Company”) (NASDAQ:
Mar 11, 2020 05:38 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Allakos Inc. (ALLK)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) in the United States District Court for the Northern District of California on behalf of those who...
Mar 11, 2020 03:22 pm ET
ALLAKOS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Allakos, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Allakos, Inc. (NASDAQ: ALLK) securities between August 5, 2019 and December 17, 2019 (the “Class Period”). Investors have until May 11, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 11, 2020 01:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Mar 11, 2020 10:10 am ET
EQUITY ALERT: Rosen Law Firm First to File Securities Class Action Lawsuit Against Allakos Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ALLK
Rosen Law Firm, a global investor rights law firm, announces it is first to file a class action lawsuit on behalf of purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class...
Mar 11, 2020 09:22 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allakos Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Allakos Inc. (“Allakos” or “the Company”) (NASDAQ:
Mar 10, 2020 06:45 pm ET
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Allakos investors under the federal securities laws.
Mar 09, 2020 05:30 pm ET
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business information to the investing public.
Feb 25, 2020 04:01 pm ET
Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the fourth quarter and full year ended December 31,...
Feb 24, 2020 08:00 am ET
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results in a...
Feb 19, 2020 07:30 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...
Feb 15, 2020 12:00 pm ET
ROSEN, A LEADING INVESTOR FIRM, Continues to Investigate Securities Claims Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business information to the investing public.
Feb 11, 2020 02:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of  Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Feb 05, 2020 04:45 pm ET
ALLK ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...
Feb 03, 2020 03:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. – ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 29, 2020 02:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of  Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 23, 2020 06:45 pm ET
ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...
Jan 16, 2020 07:40 pm ET
ALLK Investor Alert: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – A
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...
Jan 16, 2020 11:02 am ET
Block & Leviton LLP Alerts Investors of Investigations into Allakos and Sterling Bancorp for Violations of Federal Securities Laws
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors and whistleblowers nationwide, reminds investors of the Firm’s ongoing investigations of Allakos, Inc. and Sterling Bancorp, Inc. The investigations concern...
Jan 14, 2020 01:12 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or “the Company”) (NASDAQ:
Jan 09, 2020 12:09 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or “the Company”) (NASDAQ:
Jan 09, 2020 11:29 am ET
ALLK LOSS NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Announces Investigation of Securities Claims Against Allakos Inc. – ALLK
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business information to the investing public.
Jan 09, 2020 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of  Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 07, 2020 06:58 pm ET
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Allakos Inc. (ALLK) Investors
The Law Offices of Frank R. Cruz announces an investigation on behalf of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ:
Jan 06, 2020 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
NEW YORK, Jan. 6, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or the "Company") (NASDAQ: ALLK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Jan 03, 2020 07:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of  Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Jan 03, 2020 04:00 pm ET
Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Allakos Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jan 03, 2020 01:32 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Allakos Inc. Investors
Law Offices of Howard G. Smith continues its investigation on behalf of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) investors concerning the Company and its officers’ possible violations of federal securities laws.
Dec 19, 2019 08:02 pm ET
ALLAKOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Allakos, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Allakos, Inc. (NASDAQ: ALLK) on behalf of Allakos stockholders. Our investigation concerns whether Allakos has violated the federal securities laws and/or engaged in other unlawful business practices.
Dec 19, 2019 04:00 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Allakos Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) investors concerning the Company and its officers’ possible violations of federal securities laws.
Dec 19, 2019 03:04 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Allakos Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) investors concerning the Company and its officers’ possible violations of federal securities laws.
Dec 19, 2019 11:32 am ET
Allakos, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors and whistleblowers nationwide, is investigating Allakos, Inc. (NASDAQ: ALLK) and certain of its officers and directors for potential violations of federal...
Dec 18, 2019 06:50 pm ET
ALLK LOSSES ALERT: Bernstein Liebhard LLP Announces an Investigation of Allakos Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Allakos Inc. ("Allakos" or the "Company") (NASDAQ: ALLK) from allegations that Allakos might have issued misleading information to the investing public.
Dec 18, 2019 05:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK
Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...
Nov 12, 2019 04:01 pm ET
Allakos Reports Third Quarter 2019 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the third quarter ended September 30, 2019....
Oct 28, 2019 09:01 am ET
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced upcoming presentations at the American College of Gastroenterology 2019 Annual Scientific Meeting....
Aug 06, 2019 10:18 pm ET
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the upsizing and pricing of its previously announced underwritten public offering....
Aug 05, 2019 04:29 pm ET
Allakos Announces Proposed Public Offering of Common Stock
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $200 million...
Aug 05, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Allakos, AMD, Micron Technology, or QUALCOMM?
NEW YORK, Aug. 5, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, ALLK, AMD, MU, and QCOM.
Aug 05, 2019 07:15 am ET
Allakos Reports Second Quarter 2019 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the second quarter ended June 30, 2019. Second Quarter 2019...
Aug 05, 2019 07:00 am ET
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophi
Allakos Inc. (the “Company”) (Nasdaq: ALLK) today announced positive results from its Phase 2 randomized, double-blind, placebo-controlled trial of AK002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis. All AK002 dose...
May 08, 2019 08:01 am ET
Allakos Reports First Quarter 2019 Financial Results
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March 31, 2019. First Quarter 2019 Financial Results...
May 07, 2019 04:01 pm ET
Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 1 results in patients with severe allergic conjunctivitis. Patients administered...
Mar 14, 2019 04:01 pm ET
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018, and provided an...
Feb 19, 2019 08:00 am ET
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive multiple dose Phase 1 results in patients with indolent systemic mastocytosis (ISM), a...
Feb 11, 2019 08:00 am ET
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results for AK002 in patients with Xolair refractory chronic spontaneous...
Feb 04, 2019 08:00 am ET
Allakos to Host Investor Day on February 19 in New York City
Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19th starting at 12:00 pm ET in New York City. The...
Jan 29, 2019 08:00 am ET
Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results from two additional chronic urticaria cohorts: patients with cholinergic...
Jan 07, 2019 08:00 am ET
Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive top-line results for the Xolair-naïve chronic spontaneous urticaria (CSU) cohort from its...
Nov 21, 2018 07:30 am ET
New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TheStreet, Inc. (NASDAQ:TST), EVO Payments, Inc. (NASDAQ:EVOP), Odyssey...
Nov 08, 2018 04:01 pm ET
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced an update to its clinical studies and the financial results...
Oct 08, 2018 08:00 am ET
Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced the presentation of two posters at the American College of...
Aug 29, 2018 04:01 pm ET
Allakos Announces Second Quarter 2018 Financial Results
Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced financial results for the second quarter ended June 30,...
Jul 24, 2018 08:00 am ET
Allakos Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the closing of its initial public offering of...
Jul 19, 2018 07:00 am ET
Allakos Announces Pricing of Initial Public Offering
Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the pricing of its initial public offering of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.